Every Form 4 that CERO TERAPEUTICS HLDG INC (CERO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CERO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERO filings page.
CERO Therapeutics Holdings director Francois Eric received a stock option grant as equity compensation. The award covers options to buy 1,823,278 shares of Common Stock at an exercise price of $0.055 per share, held directly.
The options vest in full on the earlier of August 13, 2026 or the achievement of a specified clinical milestone in 2026, provided Eric remains in continuous service through the vesting date. The options expire on March 3, 2036, and following this grant he holds options for 1,823,278 underlying shares.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.
Cero Therapeutics Holdings, Inc. reported that Chief Development Officer Kristen Pierce received a grant of stock options on 01/07/2026. The award covers 1,612,099 stock options, each representing the right to buy one share of common stock at an exercise price of $0.055 per share. Following this grant, Pierce beneficially owns 1,612,099 derivative securities, all held in direct ownership form.
CERO Therapeutics Holdings, Inc. reported that director Shami Patel received a stock option grant. On January 7, 2026, Patel was awarded an option to buy 690,900 shares of CERO common stock at an exercise price of $0.055 per share. The option is first exercisable on January 7, 2026 and expires on January 6, 2036. After this grant, Patel beneficially owns stock options covering 690,900 shares, held as a direct ownership position.
Cero Therapeutics Holdings director reports large stock option award
Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., reported receiving a stock option covering 1,612,099 shares of the company’s common stock. The option has an exercise price of $0.055 per share, meaning he can buy up to that number of shares at this fixed price.
The option became exercisable on January 7, 2026 and is scheduled to expire on January 6, 2036, giving a 10‑year exercise window. Following this transaction, Atwood beneficially owns 1,612,099 derivative securities in the form of this stock option, which is reported as held directly.
Cero Therapeutics Holdings, Inc. reported that Chairman and CEO Christopher B. Ehrlich received a large stock option grant. On January 7, 2026, he was awarded a stock option to buy 4,530,997 shares of common stock at an exercise price of $0.055 per share. The option is exercisable from January 7, 2026 and expires on January 6, 2036. Following this grant, he beneficially owns 4,530,997 derivative securities, held as a direct ownership position, and there was no cash price paid for the option itself.
Cero Therapeutics Holdings, Inc. director Michael Byrnes received a grant of stock options on January 7, 2026. The award covers 690,900 stock options, each giving the right to buy one share of common stock at an exercise price of $0.055 per share. These options are held as direct ownership and are exercisable starting January 7, 2026, with an expiration date of January 6, 2036. The filing reports this derivative award and the resulting beneficial ownership of 690,900 derivative securities after the transaction.
Cero Therapeutics Holdings, Inc. granted its Chief Financial Officer, Andrew Kucharchuk, a stock option on January 7, 2026. The option gives the right to buy 1,162,099 shares of common stock at an exercise price of $0.055 per share. The option is listed as exercisable beginning January 7, 2026 and expires on January 6, 2036. Following this grant, Kucharchuk is reported as directly beneficially owning 1,162,099 derivative securities of this type.